Clinical Trial Update: First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line sintilimab in combination with anlotinib and platinum doublet chemotherapy for malignant pleural mesothelioma is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Malignant Pleural Mesothelioma

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Mesothelioma, Malignant, Mesothelioma, Malignant Pleural | Phase 2 | Status: RECRUITING